Mariannaeapyrone ((£,)-2-(l,3,5,7-tetramethyl-5-nonenyl)-3,5-dimethyl-6-hydroxy-4//-pyran-4-one) is a new fungal metabolite isolated from fermentations of the common mycophilic deuteromycete Mariannaea elegans. The chemical structure of the 4-pyrone was determined by spectroscopic techniques. Mariannaeapyrone is a selective inhibitor of the thromboxane A2 induced aggregation of human platelets, whereas only weak cytotoxic and antimicrobial effects could be observed.
Introduction
Platelet activation and aggregation are essential events in thrombus formation. For this reason, platelets do not only play an im portant role in hae mostasis, but they are also involved in the patho physiology of cardiovascular disorders, which may result in myocardial or ischemic cerebral infarc tion.
One im portant inducer of platelet aggregation is the prostanoid thromboxane A 2 (TX A 2), addi tionally inducing constriction of vascular and bronchiolar smooth muscle by receptor activation and thus being involved in the pathomechanism of a series of diseases. Many antagonists of the thromboxane A 2 receptor (TP receptor) have been described during the last years and some of them are under further investigation. But very often strong side effects have been detected and clinical trials on these compounds have produced very disappointing results. For this reason only a few antagonists of the TP receptor are available for use in man and only one of them, the quinone derivative 2, is m arketed so far (Bronica® by Takeda Company, Japan). There is therefore a need for novel and more potent antagonists, which are structurally different from the known entities, as they may provide more information about the TP receptor and its various functions as well as facilitate the development of novel potentially useful drugs. In the following we describe the fer m entation, isolation, structure elucidation and the biological properties of mariannaeapyrone (1 ), a new fungal m etabolite inhibiting the thromboxane A2 induced platelet aggregation.
Material and Methods

G en era l
UV and IR spectra were measured with a Perkin-Elm er Lambda 16 UV/VIS spectrometer and a B ruker IFS 48, respectively. For analytical HPLC a Hewlett Packard 1100 series instrum ent and for preparative HPLC a Jasco PU-980 instrument were used. 'H NMR (500 MHz) and 13C NMR (125 MHz) were recorded at room tem perature with a B ruker ARX500 spectrom eter with an in verse multinuclear 5 mm probehead equipped with a shielded gradient coil. The spectra were re corded in CD 3 OD, and the solvent signals (3.31 and 49.15 ppm, respectively) were used as refer ence. The chemical shifts (6 ) are given in ppm, and the coupling constants (J) in Hz. COSY, HMQC and HM BC experiments were recorded with gra dient enhancem ents using sine shaped gradient pulses. For the 2D heteronuclear correlation spectroscopy the refocusing delays were optimised for 7CH=145 Hz and n7CH=10 Hz. The raw data were transform ed and the spectra were evaluated with the standard Bruker UXNM R software (rev. 941001). Mass spectra were recorded with a Jeol 
Producing organism
Mariannaea elegans is a very common mycophilic deuteromycete. The strain UR 742 was ob tained from Dr. H. Besl, University of Regens burg, and is deposited in the culture collection of the LB Biotechnology, University of Kaiserslaut ern.
Fermentation and isolation
For maintenance on agar slants and submerged cultivation, Mariannaea elegans was grown in YMG medium composed of : yeast extract 0.4%, malt extract 1%, glucose 1%, pH 5.5 and agar 1.5% for solid media. Fermentations were carried out in a Biolafitte C6 fermenter containing 20 1 of YMG medium with aeration (2 1 air/min) and agi tation (120 rpm) at room temperature. 250 ml of a well grown culture in YMG medium were used as inoculum. During fermentation 100 ml samples were taken every day. The culture fluid was sepa rated by filtration from the mycelia and then ex tracted with 100 ml ethylacetate. The evaporated extract was dissolved in methanol and tested in the platelet aggregation assay. After seven days of fermentation the fermenters were harvested and the culture broth was separated from the mycelia. Mariannaeapyrone (1) was removed from the cul ture fluid (17 1) 32, m, 1.20, m, 1.17, d, 6 .8 , 1.15, ddd, 4.8, 9.2 and 13.5, 0.89, d, 6.7, 0.85, t, 7.4, 0.83, d, 7, . 13C NMR (CD3 OD, 125 MHz), 6 : 176.8 C-3; 169.9 C-l; 161.6 C-5; 134.3 C -ll; 133.7 C-10; 112.4 C-4; 97.2 C-2; 49.6 C-9; 43.1 C-7; 35.4 C-12; 33.7 C-6 ; 31.8 C-13; 30.1 C-8 ; 21.5 C-20; 20.1 C-18; 19.9 C-17; 16.3 C-19; 12.6 C-14; 10.5 C-16; 9.2 C-15.
Biological assays
In the platelet aggregation assay (Fabian et al., 1999) the aggregation of concentrated human platelets ( 1 x 1 0 9 cells/ml) was induced with the following agonists ADP (16 (im ), collagen (0.4 mg/ ml), U46619 (3 ^m) and TPA (12-o-tetradecanoylphorbol 13-acetate) (0.3 |a,g/ml). Cytotoxic ef fects were determined using the following mono layer cell lines: HeLa S3 (epitheloid carcinoma, cervix, human; ATCC CCL 2.2) and COS-7 (SV-40 transformed kidney fibroblasts, monkey; ATCC CRL-1651) grown in DMEM medium and the sus pension cell lines: COLO-320 (colon adenocarci noma, human; DSMZ ACC 144), HL 60 (promyelocytic leukemia, human; ATCC CCL 240) and L 1210 (lymphocytic leukemia, mouse; ATCC CCL 219) all grown in RPMI medium. Cytotoxicity was measured in microtiter plates with 1 x 1 0 5 cells/ml. After 48 hours incubation with the tested com pound the cells were examined microscopically. The effect on the growth of monolayer cell lines was measured with Giemsa stain and the viability of suspension cell lines was measured by the XTT test as described in the product information (Roche Diagnostics, Mannheim). The tested cell lines were cultivated as described elsewhere (Zapf et al., 1995 and Fabian et al., 1998). The antimicro bial activity (Anke et al., 1989) was carried out as described previously.
Results and Discussion
Fermentation, isolation and structural elucidation
The fermenters were harvested when the activ ity of the crude extract in the platelet aggregation assay reached a maximum, approximately after seven days. The extraction of the culture broth and the isolation of mariannaeapyrone (1 ) are de scribed in the experimental section. The mass spectra of 1 suggested that its elemental composi tion is C2 0 H3 2 O3 , and this was confirmed by the NMR data. The structure of 1 could be determined from the 2D COSY, NOESY, HMQC and HMBC NMR data, of which pertinent HMBC correlations are shown in Figure 2 . The HMBC correlations from the protons of the 7 methyl groups to the neighbouring carbons establish the carbon skele ton of 1 , which is in agreement with the correla tions between the protons in the open chain ob served in the COSY spectrum. C-3 is obviously a keto functionality, and the extreme chemical shifts of the carbons in the remaining two carbon-carbon double bonds support the suggestion that they are both conjugated with an EWG and have oxygen attached to the ß-carbon. With three carbon-car bon double bonds and one keto function 4 of the 5 unsaturations of mariannaeapyrone (1) are ac counted for, and the remaining must be a ring. This can only be formed between C-l and C-5, in the form of a 4-pyrone.
Biological properties
Mariannaeapyrone (1) did not inhibit the aggre gation of human platelets stimulated by ADP, col lagen and the protein kinase C activator TPA up to 312 |im (100 ng/ml) and interfered only weakly with the thrombin induced aggregation starting from 156
(50 |ig/ml). 1 is a potent inhibitor of the aggregation caused by the thromboxane A2 analogue U46619 with an IC5 0 value of 15.6 |im (5 (ig/ml). In Figure 3 , a dose-response curve for the inhibition of the U46619 induced aggregation by mariannaeapyrone (1) is shown. The inhibitory effect of 1 is strongly dependent on the concentra tion of the inducer U46619 (Fig. 4) , suggesting a competitive inhibition of the thromboxane A2 re ceptor mediated platelet aggregation by 1 .
Mariannaeapyrone showed moderate cytotoxic effects against different cell lines. The IC5 0 values varied between 125 and 250 |i m (40 and 80 ^ig/ml) and are shown in Table I In conclusion, mariannaeapyrone (1) interferes with platelet aggregation by binding to the throm boxane A2 receptor of human platelets. Interest ingly, 1 belongs to the small group of antagonists of the TP receptor lacking a carboxyl group. As reported by Yamamoto et al. (1993) , the terminal carboxyl group of 2 and 3 (Fig. 1) (1993) established that a polar group of the ligand (e.g. a hydroxyl group) interacting with Ser 2 0 1 , as well as a hydrophobic moiety are required for TP receptor antagonists of type 2 and 3. Wouters et al. (1999) showed that the benzoquinone (e.g. of 2) and benzene (e.g. of 2 and 3) rings, which are part of many inhibitors, can be replaced by other groups provided that they fit the two hy drophobic pockets identified in the receptor. On the other hand, compounds that do not fit com pletely to the postulated binding sites but still in hibiting the TP receptor have been described (Lauer et al., 1991) , and an exampel is 2-methoxy-5-methyl-l,4-benzoquinone (4). In the case of ma riannaeapyrone (1), the 4-pyrone moiety might fit into the site where the benzoquinone moiety of 2 or the phenolic moiety of 3 bind. The lipophilic side chain, however, is expected to bind to another part of the receptor. In 1986, the actinopyrones (5) isolated from a strain of Streptomyces pactum possessing vasodilatoric properties in dogs were reported , but unfortunately no data of possible antiplatelet activity have been published. For this reason, it remains unclear if the mechanism of the vasodilatoric effects reported for the actinopyrones (5) are due to an interfer ence with the TXA2 receptor mediated signal transduction.
